Polymorphisms in the promoter region of ESR2 gene and susceptibility to ovarian cancer

Gene

Volumn 546, Issue 2, 2014, Pages 283-287

  Schüler, Susanne ^a   Lattrich, Claus ^a   Skrzypczak, Maciej ^b   Fehm, Tanja ^c   Ortmann, Olaf ^a   Treeck, Oliver ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Case control study; Estrogen receptor beta; Ovarian cancer; Single nucleotide polymorphism

Indexed keywords

ESTROGEN RECEPTOR BETA;

ADULT; ALLELE; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER PATIENT; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC SUSCEPTIBILITY; GENOTYPE; HAPLOTYPE; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM;

TETRA;

CASE-CONTROL STUDY; ESTROGEN RECEPTOR BETA; OVARIAN CANCER; SINGLE NUCLEOTIDE POLYMORPHISM;

ESTROGEN RECEPTOR BETA; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; RETROSPECTIVE STUDIES;

EID: 84903535473     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2014.05.066     Document Type: Article

References (41)

1. Alvarez-Millan J.J., Bocos C., Ferrin V., Lucas A.R., Ruibal A., Schneider J. PAI-1 promoter polymorphism modulates uPA-PAI complex accumulation by breast cancer cells. Oncology 2002, 62:286-290.
2. Bardin A., Hoffmann P., Boulle N., Katsaros D., Vignon F., Pujol P., Lazennec G. Involvement of estrogen receptor beta in ovarian carcinogenesis. Cancer Res. 2004, 64:5861-5869.
3. Beleza-Meireles A., Kockum I., Lundberg F., Soderhall C., Nordenskjold A. Risk factors for hypospadias in the estrogen receptor 2 gene. J. Clin. Endocrinol. Metab. 2007, 92:3712-3718.
4. Byers M., Kuiper G.G., Gustafsson J.A., Park-Sarge O.K. Estrogen receptor-beta mRNA expression in rat ovary: down-regulation by gonadotropins. Mol. Endocrinol. 1997, 11:172-182.
5. Capurso C., Solfrizzi V., D'Introno A., Colacicco A.M., Capurso S.A., Capurso A., Panza F. Interleukin 6-174 G/C promoter gene polymorphism and sporadic Alzheimer's disease: geographic allele and genotype variations in Europe. Exp. Gerontol. 2004, 39:1567-1573.
6. Chan K.K., Wei N., Liu S.S., Xiao-Yun L., Cheung A.N., Ngan H.Y. Estrogen receptor subtypes in ovarian cancer: a clinical correlation. Obstet. Gynecol. 2008, 111:144-151.
7. Cribb A.E., Knight M.J., Dryer D., Guernsey J., Hender K., Tesch M., Saleh T.M. Role of polymorphic human cytochrome P450 enzymes in estrone oxidation. Cancer Epidemiol. Biomarkers Prev. 2006, 15:551-558.
8. Drummond A.E., Fuller P.J. The importance of ERbeta signalling in the ovary. J. Endocrinol. 2010, 205:15-23.
9. Drummond A.E., Baillie A.J., Findlay J.K. Ovarian estrogen receptor alpha and beta mRNA expression: impact of development and estrogen. Mol. Cell. Endocrinol. 1999, 149:153-161.
10. Erfani N., Razmkhah M., Talei A.R., Pezeshki A.M., Doroudchi M., Monabati A., Ghaderi A. Cytotoxic T lymphocyte antigen-4 promoter variants in breast cancer. Cancer Genet. Cytogenet. 2006, 165:114-120.
11. Fischer C., Juhasz-Boess I., Lattrich C., Ortmann O., Treeck O. Estrogen receptor beta gene polymorphisms and susceptibility to uterine fibroids. Gynecol. Endocrinol. 2010, 26:4-9.
12. Fujimura M., Hidaka T., Kataoka K., Yamakawa Y., Akada S., Teranishi A., Saito S. Absence of estrogen receptor-alpha expression in human ovarian clear cell adenocarcinoma compared with ovarian serous, endometrioid, and mucinous adenocarcinoma. Am. J. Surg. Pathol. 2001, 25:667-672.
13. Gao J., Shan G., Sun B., Thompson P.J., Gao X. Association between polymorphism of tumour necrosis factor alpha-308 gene promoter and asthma: a meta-analysis. Thorax 2006, 61:466-471.
14. Gold B., Kalush F., Bergeron J., Scott K., Mitra N., Wilson K., Ellis N., Huang H., Chen M., Lippert R., et al. Estrogen receptor genotypes and haplotypes associated with breast cancer risk. Cancer Res. 2004, 64:8891-8900.
15. Greenlee R.T., Murray T., Bolden S., Wingo P.A. Cancer statistics, 2000. CA Cancer J. Clin. 2000, 50:7-33.
16. Guillemette C., Millikan R.C., Newman B., Housman D.E. Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and association with breast cancer among African Americans. Cancer Res. 2000, 60:950-956.
17. Harendza S., Lovett D.H., Panzer U., Lukacs Z., Kuhnl P., Stahl R.A. Linked common polymorphisms in the gelatinase a promoter are associated with diminished transcriptional response to estrogen and genetic fitness. J. Biol. Chem. 2003, 278:20490-20499.
18. Hatch K.D., Beecham J.B., Blessing J.A., Creasman W.T. Responsiveness of patients with advanced ovarian-carcinoma to tamoxifen - a Gynecologic Oncology Group-study of 2nd-line therapy in 105 patients. Cancer 1991, 68:269-271.
19. Havrilesky L.J., McMahon C.P., Lobenhofer E.K., Whitaker R., Marks J.R., Berchuck A. Relationship between expression of coactivators and corepressors of hormone receptors and resistance of ovarian cancers to growth regulation by steroid hormones. J. Soc. Gynecol. Investig. 2001, 8:104-113.
20. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
21. Kitawaki J., Kado N., Ishihara H., Koshiba H., Kitaoka Y., Honjo H. Endometriosis: the pathophysiology as an estrogen-dependent disease. J. Steroid Biochem. Mol. Biol. 2002, 83:149-155.
22. Leigh Pearce C., Near A.M., Butler J.L., Van Den Berg D., Bretsky P., Conti D.V., Stram D.O., Pike M.C., Hirschhorn J.N., Wu A.H. Comprehensive evaluation of ESR2 variation and ovarian cancer risk. Cancer Epidemiol. Biomarkers Prev. 2008, 17:393-396.
23. Li A.J., Baldwin R.L., Karlan B.Y. Estrogen and progesterone receptor subtype expression in normal and malignant ovarian epithelial cell cultures. Am. J. Obstet. Gynecol. 2003, 189:22-27.
24. Lindgren P.R., Cajander S., Backstrom T., Gustafsson J.A., Makela S., Olofsson J.I. Estrogen and progesterone receptors in ovarian epithelial tumors. Mol. Cell. Endocrinol. 2004, 221:97-104.
25. Long K.C., Kauff N.D. Hereditary ovarian cancer: recent molecular insights and their impact on screening strategies. Curr. Opin. Oncol. 2011, 23(5):526-530.
26. Lurie G., Wilkens L.R., Thompson P.J., Shvetsov Y.B., Matsuno R.K., Carney M.E., Palmieri R.T., Wu A.H., Pike M.C., Pearce C.L., et al. Estrogen receptor beta rs1271572 polymorphism and invasive ovarian carcinoma risk: pooled analysis within the Ovarian Cancer Association Consortium. PLoS One 2011, 6:e20703.
27. Ogawa S., Hosoi T., Shiraki M., Orimo H., Emi M., Muramatsu M., Ouchi Y., Inoue S. Association of estrogen receptor beta gene polymorphism with bone mineral density. Biochem. Biophys. Res. Commun. 2000, 269:537-541.
28. Pennington K.P., Swisher E.M. Hereditary ovarian cancer: beyond the usual suspects. Gynecol. Oncol. 2012, 124(2):347-353.
29. Rosenkranz K., Hinney A., Ziegler A., Hermann H., Fichter M., Mayer H., Siegfried W., Young J.K., Remschmidt H., Hebebrand J. Systematic mutation screening of the estrogen receptor beta gene in probands of different weight extremes: identification of several genetic variants. J. Clin. Endocrinol. Metab. 1998, 83:4524-4527.
30. Rutherford T., Brown W.D., Sapi E., Aschkenazi S., Munoz A., Mor G. Absence of estrogen receptor-beta expression in metastatic ovarian cancer. Obstet. Gynecol. 2000, 96:417-421.
31. Scambia G., Benedetti-Panici P., Ferrandina G., Distefano M., Salerno G., Romanini M.E., Fagotti A., Mancuso S. Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy. Br. J. Cancer 1995, 72:361-366.
32. Schuit S.C., de Jong F.H., Stolk L., Koek W.N., van Meurs J.B., Schoofs M.W., Zillikens M.C., Hofman A., van Leeuwen J.P., Pols H.A., Uitterlinden A.G. Estrogen receptor alpha gene polymorphisms are associated with estradiol levels in postmenopausal women. Eur. J. Endocrinol. 2005, 153:327-334.
33. Setiawan V.W., Hankinson S.E., Colditz G.A., Hunter D.J., De Vivo I. Estrogen receptor beta (ESR2) polymorphisms and endometrial cancer (United States). Cancer Causes Control 2004, 15:627-633.
34. Stevens A., Soden J., Brenchley P.E., Ralph S., Ray D.W. Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res. 2003, 63:812-816.
35. Sundarrajan C., Liao W.X., Roy A.C., Ng S.C. Association between estrogen receptor-beta gene polymorphisms and ovulatory dysfunctions in patients with menstrual disorders. J. Clin. Endocrinol. Metab. 2001, 86:135-139.
36. Tempfer C.B., Schneeberger C., Huber J.C. Applications of polymorphisms and pharmacogenomics in obstetrics and gynecology. Pharmacogenomics 2004, 5:57-65.
37. Thellenberg-Karlsson C., Lindstrom S., Malmer B., Wiklund F., Augustsson-Balter K., Adami H.O., Stattin P., Nilsson M., Dahlman-Wright K., Gustafsson J.A., Gronberg H. Estrogen receptor beta polymorphism is associated with prostate cancer risk. Clin. Cancer Res. 2006, 12:1936-1941.
38. Treeck O., Pfeiler G., Mitter D., Lattrich C., Piendl G., Ortmann O. Estrogen receptor {beta}1 exerts antitumoral effects on SK-OV-3 ovarian cancer cells. J. Endocrinol. 2007, 193:421-433.
39. Treeck O., Elemenler E., Kriener C., Horn F., Springwald A., Hartmann A., Ortmann O. Polymorphisms in the promoter region of ESR2 gene and breast cancer susceptibility. J. Steroid Biochem. Mol. Biol. 2009, 114:207-211.
40. Yang Q., Nakamura M., Nakamura Y., Yoshimura G., Suzuma T., Umemura T., Tamaki T., Mori I., Sakurai T., Kakudo K. Correlation of prostate-specific antigen promoter polymorphisms with clinicopathological characteristics in breast cancer. Anticancer Res. 2002, 22:1825-1828.
41. Ye S., Dhillon S., Ke X., Collins A.R., Day I.N. An efficient procedure for genotyping single nucleotide polymorphisms. Nucleic Acids Res. 2001, 29:E88-88.